The GPR55 antagonist CID16020046 protects against intestinal inflammation

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• G protein-coupled receptor 55 (GPR55) is a lysophospholipid receptor implicated in various physiological processes.
• Its specific role in gut inflammatory conditions remains largely undetermined.
• Investigating GPR55's function in intestinal inflammation is crucial for understanding inflammatory mechanisms.

Purpose of the Study:

• To investigate the role of GPR55 in experimental intestinal inflammation.
• To evaluate the therapeutic potential of the GPR55 inhibitor CID16020046 in models of colitis.
• To elucidate the underlying mechanisms by which GPR55 inhibition impacts intestinal inflammation.

Main Methods:

• Experimental colitis was induced in C57BL/6 mice using dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS).
• Mice were treated daily with the GPR55 inhibitor CID16020046 (20 mg/kg).
• Inflammation scores, myeloperoxidase (MPO) activity, cytokine levels, and leukocyte recruitment were assessed. GPR55 knockout mice were also studied.

Main Results:

• CID16020046 treatment significantly reduced inflammation scores and MPO activity in both DSS and TNBS colitis models.
• Key pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, Cox-2, and STAT-3 were downregulated following GPR55 inhibition.
• GPR55 inhibition decreased leukocyte (lymphocytes, macrophages) recruitment and macrophage migration, indicating a direct effect on immune cell function.

Conclusions:

• Pharmacological blockade of GPR55 effectively ameliorates experimental intestinal inflammation.
• The therapeutic effect is mediated by reduced leukocyte migration and activation, particularly of macrophages.
• CID16020046 demonstrates potential as a novel therapeutic agent for treating inflammatory bowel diseases.